2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/2iy5wruuedsh6.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/00yc7rcvua6a7.js","/_next/static/immutable/chunks/37ktb71aq3480.js","/_next/static/immutable/chunks/2d50b-7eu4558.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/2d6noqpp6ehas.js","/_next/static/immutable/chunks/1sx186c93bpzg.js","/_next/static/immutable/chunks/3dc-1n866s65i.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2w1bvggzb0ga8.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T73c,Antifungals are the standard treatment for onychomycosis. However, oral antifungals present contraindications and potential drug-drug interactions, while topical antifungals suffer from limited efficacy and penetration. Recently, researchers have explored physical therapies, including laser and photodynamic therapy. To evaluate the clinical efficacy of combining diode laser therapy with photodynamic therapy and ciclopirox 8% hydroxypropyl chitosan (HPCH) nail lacquer in treating onychomycosis. We conducted a randomised controlled clinical trial involving patients with onychomycosis. A total of 26 patients were enrolled and followed for 12 months. Participants received either eight sessions of laser treatment combined with three sessions of photodynamic therapy, or daily treatment with ciclopirox 8% HPCH. The clinical cure rate was 94.1% in the group treated with laser and photodynamic therapy, compared to 53.3% in the group treated with ciclopirox 8% HPCH (p = 0.008). All patients who achieved clinical cure with either treatment also reached mycologic and complete cure, with a rate of 100%. The average time to healing was significantly shorter for the group receiving laser and photodynamic therapy (3.6 ± 1.2 months) than for those treated with ciclopirox 8% HPCH nail lacquer (9.2 ± 1.6 months) (p < 0.001). In the laser and photodynamic therapy group, adverse events, specifically subungual hematoma and blisters, occurred in 11.4% of patients, with a recurrence rate of 33.3%. No adverse events or recurrence were observed in patients treated with ciclopirox 8% HPCH. Treatment of onychomycosis using diode laser and photodynamic therapy results in higher clinical cure rates and shorter healing times compared to the reference treatment with 8% ciclopirox HPCH. ClinicalTrials.gov identifier: NCT05809297.31:T9bb,ABSTRACTBackgroundAntifungals are the standard treatment for onychomycosis. However, oral antifungals present contraindications and potential drug–drug interactions, while topical antifungals suffer from limited efficacy and penetration. Recently, researchers have explored physical therapies, including laser and photodynamic therapy.ObjectiveTo evaluate the clinical efficacy of combining diode laser therapy with photodynamic therapy and ciclopirox 8% hydroxypropyl chitosan (HPCH) nail lacquer in treating onychomycosis.MethodsWe conducted a randomised controlled clinical trial involving patients with onychomycosis. A total of 26 patients were enrolled and followed for 12 months. Participants received either eight sessions of laser treatment combined with three sessions of photodynamic therapy, or daily treatment with ciclopirox 8% HPCH.ResultsThe clinical cure rate was 94.1% in the group treated with laser and photodynamic therapy, compared to 53.3% in the group treated with ciclopirox 8% HPCH (p = 0.008). All patients who achieved clinical cure with either treatment also reached mycologic and complete cure, with a rate of 100%. The average time to healing was significantly shorter for the group receiving laser and photodynamic therapy (3.6 ± 1.2 months) than for those treated with ciclopirox 8% HPCH nail lacquer (9.2 ± 1.6 months) (p < 0.001). In the laser and photodynamic therapy group, adverse events, specifically subungual hematoma and blisters, occurred in 11.4% of patients, with a recurrence rate of 33.3%. No adverse events or recurrence were observed in patients treated with ciclopirox 8% HPCH.ConclusionsTreatment of onychomycosis using diode laser and photodynamic therapy results in higher clinical cure rates and shorter healing times compared to the reference treatment with 8% ciclopirox HPCH.Trial RegistrationClinicalTrials.gov identifier: NCT0580929725:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"ciclopirox: generic Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on ciclopirox (generic). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/generic/ciclopirox\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Generics\",\"item\":\"https://www.reachrx.ai/hub/tag/generic\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"ciclopirox\",\"item\":\"https://www.reachrx.ai/hub/tag/generic/ciclopirox\"}]}}"}}]],["$","$L2f",null,{"title":"ciclopirox: Research & Clinical Takeaways","description":"Explore research on ciclopirox (generic) — efficacy, safety, and comparative data.","papers":[{"doi":"10.2340/actadv.v106.adv-2026-0693","pmid":"42516099","title":"Fungal Skin Infections in Cutaneous T-cell Lymphoma Patients under Mogamulizumab Treatment","journal_title":"Acta Dermato-Venereologica","journal_issn":"1651-2057","published_at":"2026-07-28T00:00:00.000Z","url":"https://doi.org/10.2340/actadv.v106.adv-2026-0693","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-31T13:37:20.118Z","updated_at":"2026-07-31T13:37:20.118Z","tags":[{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"brand","value":"Poteligeo","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"condition","value":"Cutaneous T-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"condition","value":"Fungal Skin Infection","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"condition","value":"Mycosis Fungoides","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"condition","value":"Sézary Syndrome","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"generic","value":"amphotericin B","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"generic","value":"ciclopirox","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"generic","value":"fluconazole","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"generic","value":"mogamulizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"generic","value":"terbinafine","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"modality","value":"Anti-CCR4 Monoclonal Antibody","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"sample_size","value":"n=5","value_numeric":5},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"study_design","value":"Case Series","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"warning","value":"Causality between mogamulizumab and fungal infections cannot be established from this case series given the heavily pre-treated, immunocompromised patient population.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"warning","value":"The brand name 'Poteligeo' is inferred from mogamulizumab's known proprietary name; it is not explicitly stated in the paper.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"warning","value":"The incidence of 41.7% is from a very small single-center cohort (5/12 patients) and should be interpreted with extreme caution.","value_numeric":null}],"summaries":{"what_studied":"A single-center case series of 5 CTCL patients (1 MF, 4 SS) who developed fungal skin infections during mogamulizumab therapy between January 2021 and December 2024 at a German university center, representing 41.7% (5/12) of all mogamulizumab-treated patients at that institution.","key_result":"5 of 12 mogamulizumab-treated CTCL patients (41.7%) developed fungal skin infections at a mean of 10.6 months after therapy initiation; pathogens included *Candida* spp. (40%), *T. tonsurans* (20%), *T. rubrum* (20%), and *T. interdigitale* (20%). All infections were mild (CTCAE grade 1: 40%; grade 2: 60%); 60% required systemic antifungal therapy (terbinafine or fluconazole) after topical monotherapy failed.","limitations":"- Very small case series (n=5) from a single center; no control group or incidence comparison to other CTCL therapies.\n- Fungal infections may be attributable to the heavily pre-treated, immunocompromised baseline rather than mogamulizumab specifically.\n- Retrospective design with potential for ascertainment bias; infections could be underdiagnosed in the broader mogamulizumab literature.","practice_takeaway":"Clinicians should actively screen CTCL patients on mogamulizumab for fungal skin infections, as these can mimic CTCL lesions or mogamulizumab-associated rash (MAR) and may go undetected. Currently no antifungal prophylaxis guidelines exist for this population; a low threshold for mycological workup (culture, skin scraping, biopsy) is warranted."}},{"doi":"10.1111/myc.70121","pmid":"41024682","title":"Diode Laser and Red‐Laser Photodynamic Therapy Versus Ciclopirox 8% HPCH Nail Lacquer for the Treatment of Onychomycosis: A Randomised Controlled Trial","journal_title":"Mycoses","journal_issn":"0933-7407","published_at":"2025-09-30T00:00:00.000Z","url":"https://doi.org/10.1111/myc.70121","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-10-05","doi":"10.1111/myc.70121","days":"7","issn":"0933-7407","rank":"9","field":"Clinical Medicine","score":"1","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1111/myc.70121","title":"Diode Laser and Red-Laser Photodynamic Therapy Versus Ciclopirox 8% HPCH Nail Lacquer for the Treatment of Onychomycosis: A Randomised Controlled Trial.","journal":"Mycoses","methods":"","results":"The clinical cure rate was 94.1% in the group treated with laser and photodynamic therapy, compared to 53.3% in the group treated with ciclopirox 8% HPCH (p = 0.008). All patients who achieved clinical cure with either treatment also reached mycologic and complete cure, with a rate of 100%. The average time to healing was significantly shorter for the group receiving laser and photodynamic therapy (3.6 ± 1.2 months) than for those treated with ciclopirox 8% HPCH nail lacquer (9.2 ± 1.6 months) (p < 0.001). In the laser and photodynamic therapy group, adverse events, specifically subungual hematoma and blisters, occurred in 11.4% of patients, with a recurrence rate of 33.3%. No adverse events or recurrence were observed in patients treated with ciclopirox 8% HPCH.","abstract":"$30","keywords":["ciclopirox","laser","onychomycosis","photodynamic therapy","toluidine","topical antifungal","treatment"],"pubmed_id":"41024682","conclusions":"","publication_date":"2025-09-30T00:00:00"},"crossref":{"DOI":"10.1111/myc.70121","URL":"https://doi.org/10.1111/myc.70121","ISSN":["0933-7407","1439-0507"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/myc.70121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":"10","score":1,"title":["Diode Laser and Red‐Laser Photodynamic Therapy Versus Ciclopirox 8% HPCH Nail Lacquer for the Treatment of Onychomycosis: A Randomised Controlled Trial"],"author":[{"given":"Sara","family":"García‐Oreja","sequence":"first","affiliation":[{"name":"University Podiatry Clinic, Faculty of Nursing, Physiotherapy and Podiatry Complutense University of Madrid Madrid Spain"}]},{"given":"Francisco Javier","family":"Álvaro‐Afonso","sequence":"additional","affiliation":[{"name":"Diabetic Foot Unit, University Podiatry Clinic, Faculty of Nursing, Physiotherapy and Podiatry, Complutense University of Madrid Health Research Institute of the San Carlos Clinical Hospital (IdISSC) Madrid Spain"}]},{"given":"David","family":"Navarro‐Pérez","sequence":"additional","affiliation":[{"name":"University Podiatry Clinic, Faculty of Nursing, Physiotherapy and Podiatry Complutense University of Madrid Madrid Spain"}]},{"given":"Diego","family":"León‐Herce","sequence":"additional","affiliation":[{"name":"University Podiatry Clinic, Faculty of Nursing, Physiotherapy and Podiatry Complutense University of Madrid Madrid Spain"}]},{"given":"Aroa","family":"Tardáguila‐García","sequence":"additional","affiliation":[{"name":"Diabetic Foot Unit, University Podiatry Clinic, Faculty of Nursing, Physiotherapy and Podiatry, Complutense University of Madrid Health Research Institute of the San Carlos Clinical Hospital (IdISSC) Madrid Spain"}]},{"given":"José Luis","family":"Lázaro‐Martínez","sequence":"additional","affiliation":[{"name":"Diabetic Foot Unit, University Podiatry Clinic, Faculty of Nursing, Physiotherapy and Podiatry, Complutense University of Madrid Health Research Institute of the San Carlos Clinical Hospital (IdISSC) Madrid Spain"}]}],"issued":{"date-parts":[[2025,9,30]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":"68","archive":["Portico"],"created":{"date-time":"2025-09-30T07:39:48Z","timestamp":1759217988000,"date-parts":[[2025,9,30]]},"indexed":{"date-time":"2025-10-01T15:53:38Z","timestamp":1759334018298,"date-parts":[[2025,10,1]]},"license":[{"URL":"http://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000,"date-parts":[[2025,9,30]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/myc.70121"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-07-23"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-09-18"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-09-30"}],"deposited":{"date-time":"2025-09-30T07:39:52Z","timestamp":1759217992000,"date-parts":[[2025,9,30]]},"issn-type":[{"type":"print","value":"0933-7407"},{"type":"electronic","value":"1439-0507"}],"published":{"date-parts":[[2025,9,30]]},"publisher":"Wiley","reference":[{"DOI":"10.1111/myc.13799","key":"e_1_2_11_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1159/000485632","key":"e_1_2_11_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1177/1203475417716362","key":"e_1_2_11_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/myc.13648","key":"e_1_2_11_5_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.16394","key":"e_1_2_11_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/myc.13683","key":"e_1_2_11_7_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.20986/revesppod.2024.1695/2024","key":"e_1_2_11_8_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/archdermatol.2011.267","key":"e_1_2_11_9_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/myc.13694","key":"e_1_2_11_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/myc.13543","key":"e_1_2_11_11_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/14651858.CD010031.pub2","key":"e_1_2_11_12_1","year":"2017","issue":"7","author":"Kreijkamp‐Kaspers S.","volume":"2017","first-page":null,"unstructured":null,"article-title":"Oral Antifungal Medication for Toenail Onychomycosis","journal-title":"Cochrane Database of Systematic Reviews","doi-asserted-by":"crossref"},{"DOI":null,"key":"e_1_2_11_13_1","year":"2024","issue":"3","author":"Yousefian F.","volume":"17","first-page":"24","unstructured":null,"article-title":"Treatment Options for Onychomycosis: Efficacy, Side Effects, Adherence, Financial Considerations, and Ethics","journal-title":"Journal of Clinical and Aesthetic Dermatology","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_11_14_1","year":"2024","issue":"5","author":"Meretsky C. R.","volume":"16","first-page":null,"unstructured":null,"article-title":"Efficacy of Laser Therapy in Comparison With Other Methods for the Treatment of Onychomycosis: A Systematic Review and Meta‐Analysis","journal-title":"Cureus","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_11_15_1","year":"2020","issue":"1","author":"Foley K.","volume":"2020","first-page":null,"unstructured":null,"article-title":"Topical and Device‐Based Treatments for Fungal Infections of the Toenails","journal-title":"Cochrane Database of Systematic Reviews","doi-asserted-by":null},{"DOI":"10.3390/microbiolres16020051","key":"e_1_2_11_16_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.pdpdt.2025.104640","key":"e_1_2_11_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/jcm14051588","key":"e_1_2_11_18_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s10103‐019‐02802‐8","key":"e_1_2_11_19_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s10103-022-03561-9","key":"e_1_2_11_20_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/jof10110790","key":"e_1_2_11_21_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/jof8070742","key":"e_1_2_11_22_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_11_23_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“Prospecto Ony‐Tec 80 mg/g Barniz De Uñas Medicamentoso ”https://cima.aemps.es/cima/dochtml/p/72143/P_72143.html?msclkid=2b172500c24f11ecad173503b80e7c56.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1111/ijd.16241","key":"e_1_2_11_24_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2023.2265658","key":"e_1_2_11_25_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1159/000488606","key":"e_1_2_11_26_1","year":"2018","issue":"1","author":"Piraccini B. M.","volume":"5","first-page":"13","unstructured":null,"article-title":"Ciclopirox Hydroxypropyl Chitosan: Efficacy in Mild‐To‐Moderate Onychomycosis","journal-title":"Skin Appendage Disorders","doi-asserted-by":"crossref"},{"DOI":"10.1007/s10103-017-2198-6","key":"e_1_2_11_27_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1155/2020/1216907","key":"e_1_2_11_28_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/myc.70121"],"article-number":"e70121","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Mycoses"],"published-print":{"date-parts":[[2025,10]]},"reference-count":27,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,9,30]]},"references-count":27,"short-container-title":["Mycoses"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1111/myc.70121","is_oa":true,"title":"Diode Laser and Red‐Laser Photodynamic Therapy Versus Ciclopirox 8% HPCH Nail Lacquer for the Treatment of Onychomycosis: A Randomised Controlled Trial","updated":"2025-10-03T07:17:10+00:00","published_date":"2025-09-30","best_oa_location":{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/myc.70121","pmh_id":null,"url_for_pdf":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/myc.70121","url_for_landing_page":"https://doi.org/10.1111/myc.70121"}}},"created_at":"2025-10-08T07:09:18.220Z","updated_at":"2025-10-08T07:09:18.220Z","tags":[{"paper_doi":"10.1111/myc.70121","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1111/myc.70121","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1111/myc.70121","tag_type":"brand","value":"Ony-Tec","value_numeric":null},{"paper_doi":"10.1111/myc.70121","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/myc.70121","tag_type":"condition","value":"Onychomycosis","value_numeric":null},{"paper_doi":"10.1111/myc.70121","tag_type":"generic","value":"ciclopirox","value_numeric":null},{"paper_doi":"10.1111/myc.70121","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1111/myc.70121","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1111/myc.70121","tag_type":"modality","value":"Laser Therapy","value_numeric":null},{"paper_doi":"10.1111/myc.70121","tag_type":"modality","value":"Photodynamic Therapy","value_numeric":null},{"paper_doi":"10.1111/myc.70121","tag_type":"modality","value":"Topical Antifungal","value_numeric":null},{"paper_doi":"10.1111/myc.70121","tag_type":"sample_size","value":"n=26","value_numeric":26},{"paper_doi":"10.1111/myc.70121","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1111/myc.70121","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1111/myc.70121","tag_type":"warning","value":"Open‑label design and unequal visit frequency could bias adherence and assessments.","value_numeric":null},{"paper_doi":"10.1111/myc.70121","tag_type":"warning","value":"Outcomes were analyzed per nail; handling of patient‑level clustering was not described.","value_numeric":null},{"paper_doi":"10.1111/myc.70121","tag_type":"warning","value":"Time‑to‑healing values conflict between Table 2 and the text; the summary uses the values reported in the Results/Abstract.","value_numeric":null}],"summaries":{"what_studied":"A randomized, parallel-group trial of 26 adults with PCR/culture‑confirmed toenail onychomycosis compared eight sessions of diode laser (810/1064 nm) plus red‑laser photodynamic therapy (635 nm, toluidine blue) over 9 weeks versus daily ciclopirox 8% HPCH nail lacquer for at least 9 months, with 12‑month follow‑up.","key_result":"Clinical cure per nail was 94.1% with laser+PDT (16/17) vs 53.3% with ciclopirox (8/15) (p=0.008; OR 0.071, 95% CI 0.007–0.685); all clinically cured nails achieved mycologic and complete cure (100%). Time to healing was shorter with laser+PDT (3.6±1.2 vs 9.2±1.6 months; p<0.001); adverse events occurred in 11.4% of treated nails (all laser+PDT; subungual hematoma/blisters) and recurrences occurred in 6/24 cured nails (33.3% of laser+PDT patients), with none in the ciclopirox group.","limitations":"Small, single-center, open-label study with all procedures performed by one podiatrist. Microbiologic cultures were only repeated in clinically cured nails, which may overstate mycologic cure. Post‑treatment observation time and visit intensity differed between groups, potentially affecting recurrence and adherence.","practice_takeaway":"For adults who cannot take oral antifungals, an 8‑session diode laser plus red‑laser PDT protocol achieved higher clinical cure and faster healing than daily ciclopirox 8% HPCH, but with mild local adverse events and more recurrences in this small RCT. Consider selectively, pending confirmation in larger, blinded, multicenter trials."}}],"initialOffset":2,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"generic","value":"ciclopirox"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Generics","href":"/hub/tag/generic"},{"name":"ciclopirox"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"generic","hub_tag_value":"ciclopirox"}}}]]

Papers